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THE RATIO OF PUBLIC REIMBURSEMENT AND PATIENTS’ CO-PAYMENT IN THE
FINANCING OF SPA SERVICES IN HUNGARY
Turcsanyi K1, Domján P1, Boncz I2
1University of Pécs, Zalaegerszeg, Hungary, 2University of Pécs, Pécs, Hungary
OBJECTIVES:Hungary has long and strong traditions in providing spa services. The
reimbursement of spa services includes both public health insurance scheme and
patient co-payment. The aim of our study is to explore the ratio of public reim-
bursement and patients’ co-payment in financing of spa services in Hungary.
METHODS: Data were derived from the nationwide administrative dataset of the
National Health Insurance Fund Administration (OEP), the only health care financ-
ing agency in Hungary covering the year 2007. We calculated within the total spa
spending the annual health insurance reimbursement and the patients’ co-pay-
ment at county and regional level. Hunmgary is devided into 7 regions and 20
counties. RESULTS: On nationwide level, the average ratio of patients’ co-payment
was 28.0 %, while the remaining 72.0 % was reimbursed by the National Health
Insurance Fund Administration (OEP). At regional level, the ratio of patients’ co-
payment varied between 22.7 % (in the Northern-Great Plane region) and 35.4 % (in
the Western-Transdanubian region). At county level, we found the lowest ratio of
patients’ co-payment in county Csongrád (19.8 %), Hajdú-Bihar (21.3 %) and Békés
(23.1 %), while the highest ratio of patients’ co-payment was observed in county
Zala (53.4 %), Veszprém (46.6 %) and Somogy (33.3 %). CONCLUSIONS: In financing
of spa services in Hungary, patient co-payment has a significant role: 28.0 % of total
expenditures. There are important inequalities in the ratio of patient co-payment
at both regional and county level.
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OBJECTIVES: Home care (nursing) was introduced into the Hungarian basic health
insurance package in 1996. The aim of our study is to analyze the geographical
inequalities in home care (nursing) in Hungary.METHODS:Data were derived from
the nationwide administrative dataset of the National Health Insurance Fund Ad-
ministration (OEP), the only health care financing agency in Hungary. The utiliza-
tion of home care (nursing) services was measured by the number of patients and
the number of visits. The geographical inequalities were calculated for county
level. Both indicator was calculated to 10.000 population. RESULTS: The average
number of patients in the Hungarian home care system was 50 / 10.000 population.
We found the highest utilization in the following counties: Zala (65), Baranya (65),
Jász-Nagykun-Szolnok (64), Vas (59), Csongrád (54), Borsod-Abaúj-Zemplén (54)
and Gyõr-Moson-Sopron counties. The lowest utilization rate was measured in
Komárom-Esztergom (43), Fejér (43), Noˇgrád (38) and Szabolcs-Szatmár-Bereg (26)
counties (all are for 10.000 population). The average number of home care visits
was 1188 visits/10.000 population at national level. The number of home visits was
the highest in Fejér (1342), Komárom-Esztergom (1333), Jász-Nagykun-Szolnok
(1327), Noˇgrád (1310), Gyõr-Moson-Sopron (1285) counties. The lowest home visit
rate was measured in Budapest (1162), Somogy (1142) and Szabolcs-Szatmár-Bereg
(614) counties (all are for 10.000 population). CONCLUSIONS: We found significant
inequalities in the utilization of home care (nursing) in Hungary measured both by
the number of patients and the number of visits per 10.000 population.
PHP15
IMPLICATIONS OF LATIN AMERICAN PHARMACEUTICAL PRICING REFORM FOR
THE UK NHS
Shankland BDT, Kirpekar S
Double Helix Consulting, London, UK
OBJECTIVES: Mexico and Brazil have well-developed pharmaceutical pricing sys-
tems, with an increasing trend towards use of Health Technology Assessment in
access decisions. However, there are significant differences in the prices of inno-
vative medicines in the two countries. The object of the study is to clarify to what
extent local decision making criteria can account for these discrepancies and
therefore which evaluation mechanisms may have international relevance.
METHODS: Secondary research was carried out to identify prices in Brazil and
Mexico for 5 patented oncology medicines. A rating scale was then devised with the
following decision domains for pricing and reimbursement: international referenc-
ing; cost-plus analysis; economic evaluation and budget impact; innovation; un-
met needs; therapeutic referencing; negotiated agreements; demand side controls;
and societal benefit. In primary research 4 senior stakeholders in Brazil and Mexico
were asked to rate the importance of these domains in access decisions, and pro-
vide a rationale. RESULTS: Decision criteria in Mexico and Brazil reflect the histor-
ical origins of their respective health systems, but recent developments reflect a
centralising trend in decision-making in both countries. This suggests that eco-
nomic evaluation will increasingly determine access in both countries but pricing
criteria will remain different, notably due to the greater role of price negotiation in
Mexico. CONCLUSIONS: The mix of empirical and context-based decision criteria
in Brazil and Mexico represent valuable alternative models for other countries,
such as the UK National Health Service (NHS), which is currently contemplating a
move towards “value-based pricing” for pharmaceuticals. In particular, Mexican
and Brazilian evaluation mechanisms may inform future considerations of thera-
peutic innovation in the UK.
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OBJECTIVES: The study sought to estimate the waiting time and assess its impli-
cations on the utilization of antenatal services in the Asante Akim North Munici-
pal, Ghana. METHODS: The study was a cross sectional descriptive type using both
qualitative and quantitative methods. In all 200 pregnant women presenting at the
Konongo Odumasi Government Hospital and the Agogo Presbyterian Hospital were
randomly selected for the study. Structured questionnaires were used to obtain
data from respondents. Key informant and household heads interviews were also
conducted and used to augment the information obtained. Descriptive and infer-
ential statistics were used in the data analysis; statistical differences were set at
0.05 or less and at 95% confidence interval. RESULTS: Of the 200 respondents 35.5%
(71) made four visits and 64.5% (129) made one or more visits. Pregnant mothers
had to forego GH¢ 31(US$ 22.14) and GH¢ 15(US$10.17) as their incomes whenever
they attended ANC. Significant differences existed between national health insur-
ance policy holders and antennal clinic (ANC) visits (p0.022), trimester of preg-
nancy and ANC visits (p0.001), and place of residence (indicating distance to
health facility and ANC visits (p0.017). CONCLUSIONS: Long waiting is associated
with high opportunity cost and are likely to reduce utilisation of ANC services in a
free services provision setting. Further studies on feasibility of creating of separate
pharmacy, laboratory and records units for antenatal clinic users and effects of
waiting time on service utilization may be helpful to improve utilization of ANC
services and reduction in pregnancy related maternal mortality.
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BACKGROUND: Essential medicines are those that satisfy the priority health care
needs of the population. They are selected with due regard to public health rele-
vance, evidence on efficacy and safety, and comparative cost-effectiveness. To be
selected, medicines must be available through health systems, in suitable amounts
and dosage forms. The Essential Medicines List can help countries rationalize the
purchasing and distribution of medicines, thereby reducing costs to the health
system. Most countries have national lists and some have provincial, state or in-
stitutional lists as well. Mexican Health System has 2 main institutions who pro-
vide healthcare services to population: IMSS and ISSSTE; each of them have an
institutional list and also there is a National essential medicine list. OBJECTIVES:
To compare the National essential medicine list with the institutional lists of IMSS
and ISSSTE. METHODS: The National essential medicine list (2009 version) and the
latest web versions available for the essential list of each institution where ana-
lyzed to compare by product key and by generic name for each of the 23 therapeutic
groups excluding the groups referring to vaccines, nutrimental components and
electrolytic solutions.RESULTS:There were a wide difference between the national
essential list and the institutional list especially in the group for treating endocri-
nology, oncology and infectius conditions. Also there were big differences for more
than 50% of the therapeutic groups examined between the institutions.
CONCLUSIONS: There remains, significant opportunity for improvement of the
national and institutional essential medicines list because don=t seem to be uni-
form criteria to selection.
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OBJECTIVOS: Analizar el ahorro en costos por la intervención del farmacéutico
sobre errores de prescripción, desde la perspectiva del proveedor de servicios de
salud. METODOLOGÍAS: Análisis de costo-efectividad, tipo árbol de decisiones. Se
estimaron costos y efectividades de incluir en las decisiones médicas un farma-
céutico y corregir prescripciones de antihipertensivos e hipoglucemiantes combi-
nados con analgésicos e hipolipemiantes. La medida de efectividad fue la probabi-
lidad de otorgar prescripciones farmacológicas sin eventos adversos graves (EAG),
con horizonte temporal de 30 días. La probabilidad de corrección por la interven-
ción del farmacéutico se obtuvo a través de un ensayo clínico (EC) y la probabilidad
de la ocurrencia de EAG (hemorragia gastrointestinal, rabdoimiolisis, enfermedad
vascular cerebral y fractura de cadera) como consecuencia de la no corrección se
obtuvo de la literatura publicada. Se estimaron los costos de la atención médica con
y sin farmacéutico del EC y los costos esperados de los EAG de publicaciones de
costos nacionales. Los costos son expresados en pesos mexicanos del 2010.
RESULTADOS: Costo promedio por paciente esperado sin la intervención del
farmacéutico durante el horizonte temporal fue de $12,481.60 y el costo promedio
por paciente con la intervención fue de $9,127.97, lo que significó disminución en el
costo por paciente de 27%. El número de prescripciones que evitaron interacciones
riesgosas fue superior con la presencia del farmacéutico y la posibilidad de que un
paciente no presentara alguno de los desenlaces evaluados por efecto de la inter-
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